All Stories

  1. Immune Checkpoint Inhibitors and Bone Health: Mechanisms, Clinical Implications, and Emerging Perspectives on Bone Fragility
  2. Evaluation of Inflammatory Parameters and Ferritin as Prognostic Factors in Non-small Cell Lung Cancer Patients Receiving Nivolumab Immunotherapy
  3. THE EXPRESSION AND PROGNOSTIC SIGNIFICANCE OF IDH1-R132H MUTATION IN ENDOMETRIAL CARCINOMA
  4. Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study
  5. LOCALIZE SCROTAL KAPOSI SARCOMA IN A HIV-NEGATIVE PATIENT
  6. Prognostic value of IMDC score in non-small cell lung cancer receiving immunotherapy: old dog, new tricks?
  7. The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
  8. Comparison of granisetron and palonosetron in triplet anti-emetic prophylaxis in non-small cell lung cancer patients receiving cisplatin-based highly emetogenic chemotherapy
  9. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study
  10. BEFORE & AFTER: THE EVALUATION OF THE EFFECT OF THE COVID-19 PANDEMIC ON CANCER PATIENTS IN PALLIATIVE CARE CENTER
  11. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and Management from the Turkish Oncology Group (TOG)
  12. The Utility of the Cachexia Index and the Modified Glasgow Score in Young Patients With Breast Cancer
  13. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study
  14. Cancer Care After the Earthquake? What Is Left to Us?
  15. The correlation between pre-treatment CEA levels and the EGFR mutation status in advanced lung adenocarcinoma
  16. After an Earthquake: The Comparison of Psychological Status of Resident and Earthquake Survivor Cancer Patients
  17. Laboratory Parameters Predicting Brain Metastasis in Patients with Lung Cancer
  18. The efficacy of IMDC score in Malignant Melanoma
  19. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
  20. Kanser hastalarında aşılanma durumu ve aşılanmayı etkileyen faktörlerin değerlendirilmesi
  21. Three Perspectives: The Approach of Neoadjuvant Treatment of Rectum Cancer According to Medical Oncologists, Radiation Oncologists, and Surgeons
  22. A New Prognostic Index in Young Breast Cancer Patients
  23. Microsatellite instability (MSI) in endometrial cancer; frequency and prognostic significance
  24. The Effect of COVID-19 on Radiation Oncology Practice in Türkiye
  25. Real-Life Analysis of Efficacy and Safety of Everolimus Plus Exemestane in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Metastatic Breast Cancer Patients: A Turkish Oncology Group (TOG) Study
  26. The Effect of The Body Composition to Prognosis in Young Breast Cancer Patients
  27. Prognostic Value of Systemic Immune Index in Patients with Metastatic Gastric Cancer
  28. Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience
  29. The effect of body composition on prognosis in critically ill COVID-19 patients
  30. Investigation of the Effect of Tumor Location in Patients with Stage III Colon Cancer Receiving Adjuvant Oxaliplatine-Based Adjuvant Chemotherapy
  31. The View of Turkish Oncologists Regarding MSI Status and Tumor Localization in Stage II and III Colon Cancer
  32. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients
  33. Intravenous Chemotherapy Adherence of Cancer Patients in Time of Covid-19 Crisis
  34. The Real-Life Data of BRAF Mutation on the Treatment of Colorectal Cancer: a TOG Study
  35. Adjuvant chemotherapy in gastric cancer
  36. The Effect of The Body Composition to Prognosis in Young Breast Cancer Patients
  37. Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
  38. The Comparison of Central Venous Port Catheters in Gastrointestinal Cancer Treatment
  39. The Effect of the Prognostic Nutritional Index on Chemoradiotherapy Response in Lung Cancer
  40. P1.14-15 Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
  41. The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group
  42. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study
  43. Are preoperative serum CA15-3 levels different in breast cancer subgroups?
  44. Does Vitamin D Replacement Alter the Chemotherapy Outcome in Lung Cancer
  45. Is TTF-1 a prognostic marker in non-small cell lung adenokarsinoma?
  46. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes
  47. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy. A multicenter, prospective, and observational study
  48. Efficiency and safety of regorafenib in metastatic colorectal cancer (mCRC): Real life experience from Turkey.
  49. Cetuximab Treatment for Head and Neck Skin Cancer in a Patient with Heart Transplantation
  50. The Relationship Between the Level of Parathormone and the Existence and the Degree of Coronary Atherosclerosis
  51. Oxaliplatin induced acute immune-mediated thrombocytopenia; a case report